Technology
Health
Biotechnology

NewLink Genetics

$1.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (4.42%) Today
-$0.10 (-5.29%) After Hours

Why Robinhood?

You can buy or sell NLNK and other stocks, options, ETFs, and crypto commission-free!

About

NewLink Genetics Corporation Common Stock, also called NewLink Genetics, is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Read More The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Employees
55
Headquarters
Ames, Iowa
Founded
1999
Market Cap
70.45M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
482.90K
High Today
$1.90
Low Today
$1.78
Open Price
$1.80
Volume
335.82K
52 Week High
$5.61
52 Week Low
$1.28

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

News

Markets InsiderMay 6

NewLink Genetics to Participate in Upcoming Investor and Medical Conferences

AMES, Iowa, May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas Management will present on Thursday, May 16 at 8:40 AM PT / 11:40 AM ET Immuno-Oncology 2019 World Congress on May 23-24 in Barcelona, Spain Poster presentation of Abstract #188 entitled, “A Phase 1 Clinical Trial of NLG802, a...

93
Yahoo FinanceApr 26

NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued

NewLink Genetics Corporation's (NASDAQ:NLNK) released its most recent earnings update in December 2018, which indicated that losses became smaller relative to the prior year's level - great news for investors Below, I've presented key growth figures on how market analysts perceive NewLink Genetics's earnings growth outlook over the next few years and whether the future looks brighter.

117

Earnings

-$0.77
-$0.58
-$0.39
-$0.20
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.